Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company developing therapies for neurological and psychiatric disorders, with its lead candidate azetukalner, a Kv7 potassium channel opener, undergoing clinical trials for epilepsy and neuropsychiatric indications including major depressive disorder and bipolar depression. The company targets large patient populations with significant unmet medical needs, including millions suffering from drug-resistant seizures and treatment-resistant depression. Xenon has no approved products or commercial revenue to date; it plans to generate revenue through direct commercialization of lead candidates, strategic partnerships, and licensing arrangements, with patent protection extending into the coming decades and a recent major collaboration involving substantial milestone and royalty payments.